Aegerion Pharmaceuticals Announces Date of FDA Advisory Committee Review of Lomitapide NDA
Aegerion Pharmaceuticals, Inc. (Nasdaq: AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating and often fatal rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has scheduled a meeting of the Endocrinologic and Metabolic Drugs Advisory Committee on October 17, 2012, to review the Company's New Drug Application for lomitapide in the treatment of adult patients with Homozygous Familial Hypercholesterolemia (HoFH). Details of the meeting will be available in the Federal Register.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.